{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:39:34Z","timestamp":1786981174843,"version":"build-2736575974"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T00:00:00Z","timestamp":1675900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T00:00:00Z","timestamp":1675900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008810","name":"NSW Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008810","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Interv Card Electrophysiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ventricular tachycardia (VT) is associated with significantly increased morbidity and mortality. Catheter ablation (CA) in line with an implantable cardioverter-defibrillator (ICD) is highly effective in VT management; however, it is unknown if CA should be considered as first-line therapy. The aim of this study is to verify the efficacy and safety of CA as first-line therapy for the first VT presentation (as adjunctive to ICD insertion), compared to initial ICD insertion and anti-arrhythmic drug (AAD) therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data from patients with the first presentation for VT from January 2017 to January 2021 was reviewed. Patients were classified as \u201cablation first\u201d vs \u201cICD first\u201d groups and compared the clinical outcomes between groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      One hundred and eighty-four consecutive patients presented with VT; 34 underwent CA as first-line therapy prior to ICD insertion, and 150 had ICD insertion\/AAD therapy as first\u2010line. During the median follow-up of 625\u00a0days, patients who underwent CA as first-line therapy had significantly higher ventricular arrhythmia (VA)-free survival (91% vs 59%, log-rank\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.002) and composite of VA recurrence, cardiovascular hospitalization, transplant, and death (84% vs 54%, log-rank\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.01) compared to those who did not undergo CA. Multivariate analysis revealed that first-line CA was the only protective predictor of VA recurrence (hazard ratio (HR) 0.20,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.003). There were 3 (9%) peri-procedural complications with no peri-procedural deaths.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Real-world data supports the efficacy and safety of CA as first-line therapy at the time of the first VT hospitalization, compared to the initial ICD implant and AAD therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10840-023-01483-2","type":"journal-article","created":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T07:14:57Z","timestamp":1675926897000},"page":"1701-1711","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Efficacy and safety of catheter ablation as first-line therapy for the management of ventricular tachycardia"],"prefix":"10.1007","volume":"66","author":[{"given":"Yasuhito","family":"Kotake","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaimin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasun","family":"De Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwin","family":"Bhaskaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Kanawati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samual","family":"Turnbull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5643-5076","authenticated-orcid":false,"given":"Saurabh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,9]]},"reference":[{"key":"1483_CR1","doi-asserted-by":"publisher","first-page":"e190","DOI":"10.1016\/j.hrthm.2017.10.035","volume":"15","author":"SM Al-Khatib","year":"2018","unstructured":"Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA\/ACC\/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart Rhythm. 2018;15:e190\u2013252.","journal-title":"Heart Rhythm"},{"key":"1483_CR2","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1016\/j.hrthm.2015.08.020","volume":"12","author":"A Sabbag","year":"2015","unstructured":"Sabbag A, Suleiman M, Laish-Farkash A, et al. Contemporary rates of appropriate shock therapy in patients who receive implantable device therapy in a real-world setting: from the Israeli ICD registry. Heart Rhythm. 2015;12:2426\u201333.","journal-title":"Heart Rhythm"},{"key":"1483_CR3","volume":"32","author":"Y Kotake","year":"2021","unstructured":"Kotake Y, Yasuoka R, Tanaka M, et al. Comparison of second appropriate defibrillator therapy occurrence in patients implanted for primary prevention and secondary prevention - sub-analysis of the Nippon Storm Study. Int J Cardiol Heart Vasc. 2021;32: 100704.","journal-title":"Int J Cardiol Heart Vasc"},{"key":"1483_CR4","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1056\/NEJMoa071098","volume":"359","author":"JE Poole","year":"2008","unstructured":"Poole JE, Johnson GW, Hellkamp AS, et al. Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med. 2008;359:1009\u201317.","journal-title":"N Engl J Med"},{"key":"1483_CR5","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/j.jacc.2007.09.073","volume":"51","author":"JP Daubert","year":"2008","unstructured":"Daubert JP, Zareba W, Cannom DS, et al. Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact. J Am Coll Cardiol. 2008;51:1357\u201365.","journal-title":"J Am Coll Cardiol"},{"key":"1483_CR6","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1056\/NEJMoa065457","volume":"357","author":"VY Reddy","year":"2007","unstructured":"Reddy VY, Reynolds MR, Neuzil P, et al. Prophylactic catheter ablation for the prevention of defibrillator therapy. N Engl J Med. 2007;357:2657\u201365.","journal-title":"N Engl J Med"},{"key":"1483_CR7","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(09)61755-4","volume":"375","author":"KH Kuck","year":"2010","unstructured":"Kuck KH, Schaumann A, Eckardt L, et al. Catheter ablation of stable ventricular tachycardia before defibrillator implantation in patients with coronary heart disease (VTACH): a multicentre randomised controlled trial. Lancet. 2010;375:31\u201340.","journal-title":"Lancet"},{"issue":"3","key":"1483_CR8","doi-asserted-by":"publisher","first-page":"e004422","DOI":"10.1161\/CIRCEP.116.004422","volume":"10","author":"KH Kuck","year":"2017","unstructured":"Kuck KH, Tilz RR, Deneke T, et al. Impact of substrate modification by catheter ablation on implantable cardioverter-defibrillator interventions in patients with unstable ventricular arrhythmias and coronary artery disease: results from the multicenter randomized controlled SMS (Substrate Modification Study). Circ Arrhythm Electrophysiol. 2017;10(3):e004422.","journal-title":"Circ Arrhythm Electrophysiol."},{"issue":"25","key":"1483_CR9","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1161\/CIRCULATIONAHA.122.059598","volume":"145","author":"P Della Bella","year":"2022","unstructured":"Della Bella P, Baratto F, Vergara P, et al. Does timing of ventricular tachycardia ablation affect prognosis in patients with an implantable cardioverter defibrillator? Results from the multicenter randomized PARTITA trial. Circulation. 2022;145(25):1829\u201338.","journal-title":"Circulation."},{"key":"1483_CR10","first-page":"374","volume":"4","author":"J Romero","year":"2018","unstructured":"Romero J, Di Biase L, Diaz JC, et al. Early versus late referral for catheter ablation of ventricular tachycardia in patients with structural heart disease: a systematic review and meta-analysis of clinical outcomes. J Am Coll Cardiol EP. 2018;4:374\u201382.","journal-title":"J Am Coll Cardiol EP"},{"key":"1483_CR11","first-page":"810","volume":"4","author":"J Romero","year":"2018","unstructured":"Romero J, Stevenson WG, Fujii A, et al. Impact of number of oral antiarrhythmic drug failures before referral on outcomes following catheter ablation of ventricular tachycardia. J Am Coll Cardiol EP. 2018;4:810\u20139.","journal-title":"J Am Coll Cardiol EP"},{"key":"1483_CR12","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1111\/j.1540-8167.2011.02081.x","volume":"22","author":"DS Frankel","year":"2011","unstructured":"Frankel DS, Mountantonakis SE, Robinson MR, Zado ES, Callans DJ, Marchlinski FE. Ventricular tachycardia ablation remains treatment of last resort in structural heart disease: argument for earlier intervention. J Cardiovasc Electrophysiol. 2011;22:1123\u20138.","journal-title":"J Cardiovasc Electrophysiol"},{"key":"1483_CR13","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1161\/CIRCULATIONAHA.119.043400","volume":"141","author":"S Willems","year":"2020","unstructured":"Willems S, Tilz RR, Steven D, et al. Preventive or deferred ablation of ventricular tachycardia in patients with ischemic cardiomyopathy and implantable defibrillator (BERLIN VT): A Multicenter Randomized Trial. Circulation. 2020;141:1057\u201367.","journal-title":"Circulation"},{"issue":"25","key":"1483_CR14","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1161\/CIRCULATIONAHA.122.060039","volume":"145","author":"R Tung","year":"2022","unstructured":"Tung R, Xue Y, Chen M, et al. First-line catheter ablation of monomorphic ventricular tachycardia in cardiomyopathy concurrent with defibrillator implantation: the PAUSE-SCD randomized trial. Circulation. 2022;145(25):1839\u201349.","journal-title":"Circulation."},{"key":"1483_CR15","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1093\/eurheartj\/ehm342","volume":"29","author":"P Elliott","year":"2008","unstructured":"Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2008;29:270\u20136.","journal-title":"Eur Heart J"},{"key":"1483_CR16","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1136\/postgradmedj-2015-133550","volume":"91","author":"KL Looi","year":"2015","unstructured":"Looi KL, Tang A, Agarwal S. Ventricular arrhythmia storm in the era of implantable cardioverter-defibrillator. Postgrad Med J. 2015;91:519\u201326.","journal-title":"Postgrad Med J"},{"key":"1483_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s10840-021-01088-7","author":"Y Kotake","year":"2021","unstructured":"Kotake Y, Nalliah CJ, Campbell T, Bennett RG, Turnbull S, Kumar S. Comparison of the arrhythmogenic substrate for ventricular tachycardia in patients with ischemic vs non-ischemic cardiomyopathy - insights from high-density, multi-electrode catheter mapping. J Interv Card Electrophysiol. 2021. https:\/\/doi.org\/10.1007\/s10840-021-01088-7.","journal-title":"J Interv Card Electrophysiol."},{"key":"1483_CR18","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.120.009408","volume":"14","author":"R Bennett","year":"2021","unstructured":"Bennett R, Campbell T, De Silva K, Bhaskaran A, Kumar S. Catheter ablation of ventricular tachycardia guided by substrate electrical inexcitability. Circ Arrhythm Electrophysiol. 2021;14: e009408.","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"1483_CR19","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1161\/CIRCEP.114.002145","volume":"8","author":"S Kumar","year":"2015","unstructured":"Kumar S, Barbhaiya C, Nagashima K, et al. Ventricular tachycardia in cardiac sarcoidosis: characterization of ventricular substrate and outcomes of catheter ablation. Circ Arrhythm Electrophysiol. 2015;8:87\u201393.","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"12","key":"1483_CR20","doi-asserted-by":"publisher","first-page":"e005005","DOI":"10.1161\/CIRCEP.117.005005","volume":"10","author":"A Fujii","year":"2017","unstructured":"Fujii A, Nagashima K, Kumar S, et al. Significance of inducible nonsustained ventricular tachycardias after catheter ablation for ventricular tachycardia in ischemic cardiomyopathy. Circ Arrhythm Electrophysiol. 2017;10(12):e005005.","journal-title":"Circ Arrhythm Electrophysiol."},{"key":"1483_CR21","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.hrthm.2018.01.013","volume":"15","author":"M Watanabe","year":"2018","unstructured":"Watanabe M, de Riva M, Piers SRD, et al. Fast nonclinical ventricular tachycardia inducible after ablation in patients with structural heart disease: definition and clinical implications. Heart Rhythm. 2018;15:668\u201376.","journal-title":"Heart Rhythm"},{"key":"1483_CR22","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1016\/j.jacc.2022.01.050","volume":"79","author":"A Arenal","year":"2022","unstructured":"Arenal A, Avila P, Jimenez-Candil J, et al. Substrate ablation vs antiarrhythmic drug therapy for symptomatic ventricular tachycardia. J Am Coll Cardiol. 2022;79:1441\u201353.","journal-title":"J Am Coll Cardiol"},{"key":"1483_CR23","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.hrthm.2017.10.009","volume":"15","author":"JR Winterfield","year":"2018","unstructured":"Winterfield JR, Kent AR, Karst E, et al. Impact of ventricular tachycardia ablation on health care utilization. Heart Rhythm. 2018;15:355\u201362.","journal-title":"Heart Rhythm"},{"key":"1483_CR24","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.cjca.2018.10.011","volume":"35","author":"A Porta-Sanchez","year":"2019","unstructured":"Porta-Sanchez A, Ha ACT, Wang X, et al. Health care utilization after ventricular tachycardia ablation: a propensity score-matched cohort study. Can J Cardiol. 2019;35:169\u201377.","journal-title":"Can J Cardiol"},{"key":"1483_CR25","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1513614","volume":"375","author":"JL Sapp","year":"2016","unstructured":"Sapp JL, Wells GA, Parkash R, et al. Ventricular tachycardia ablation versus escalation of antiarrhythmic drugs. N Engl J Med. 2016;375:111\u201321.","journal-title":"N Engl J Med"},{"key":"1483_CR26","first-page":"13","volume":"5","author":"J Romero","year":"2019","unstructured":"Romero J, Cerrud-Rodriguez RC, Di Biase L, et al. Combined endocardial-epicardial versus endocardial catheter ablation alone for ventricular tachycardia in structural heart disease: a systematic review and meta-analysis. J Am Coll Cardiol EP. 2019;5:13\u201324.","journal-title":"J Am Coll Cardiol EP"},{"key":"1483_CR27","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1161\/01.CIR.101.25.2981","volume":"101","author":"MG Sutton","year":"2000","unstructured":"Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation. 2000;101:2981\u20138.","journal-title":"Circulation"},{"key":"1483_CR28","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1161\/01.CIR.81.4.1161","volume":"81","author":"MA Pfeffer","year":"1990","unstructured":"Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation. 1990;81:1161\u201372.","journal-title":"Circulation"},{"key":"1483_CR29","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1161\/01.CIR.76.1.44","volume":"76","author":"HD White","year":"1987","unstructured":"White HD, Norris RM, Brown MA, Brandt PW, Whitlock RM, Wild CJ. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation. 1987;76:44\u201351.","journal-title":"Circulation"},{"key":"1483_CR30","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.hrthm.2017.01.019","volume":"14","author":"D Penela","year":"2017","unstructured":"Penela D, Acosta J, Andreu D, et al. Identification of the potentially arrhythmogenic substrate in the acute phase of ST-segment elevation myocardial infarction. Heart Rhythm. 2017;14:592\u20138.","journal-title":"Heart Rhythm"},{"key":"1483_CR31","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1161\/CIRCEP.113.000348","volume":"6","author":"CH Hsieh","year":"2013","unstructured":"Hsieh CH, Chia EM, Huang K, et al. Evolution of ventricular tachycardia and its electrophysiological substrate early after myocardial infarction: an ovine model. Circ Arrhythm Electrophysiol. 2013;6:1010\u20137.","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"1483_CR32","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1016\/j.hrthm.2014.07.012","volume":"11","author":"C Palaniswamy","year":"2014","unstructured":"Palaniswamy C, Kolte D, Harikrishnan P, et al. Catheter ablation of postinfarction ventricular tachycardia: ten-year trends in utilization, in-hospital complications, and in-hospital mortality in the United States. Heart Rhythm. 2014;11:2056\u201363.","journal-title":"Heart Rhythm"},{"key":"1483_CR33","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1111\/jce.13452","volume":"29","author":"DF Briceno","year":"2018","unstructured":"Briceno DF, Gupta T, Romero J, et al. Catheter ablation of ventricular tachycardia in nonischemic cardiomyopathy: a propensity score-matched analysis of in-hospital outcomes in the United States. J Cardiovasc Electrophysiol. 2018;29:771\u20139.","journal-title":"J Cardiovasc Electrophysiol"}],"container-title":["Journal of Interventional Cardiac Electrophysiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10840-023-01483-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10840-023-01483-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10840-023-01483-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T02:09:55Z","timestamp":1696298995000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10840-023-01483-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,9]]},"references-count":33,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,10]]}},"alternative-id":["1483"],"URL":"https:\/\/doi.org\/10.1007\/s10840-023-01483-2","relation":{},"ISSN":["1572-8595"],"issn-type":[{"value":"1572-8595","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,9]]},"assertion":[{"value":"10 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Missing Open Access funding information has been added in the Funding Note.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"An analysis of this data was approved by the Human Research Ethics Committee of Westmead Hospital and complies with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained in all cases included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Dr. Kumar has received research grants from Abbott Medical and Biotronik; he has received honoraria from Biosense Webster, Abbott Medical, Biotronik, and Sanofi Aventis. Mr. Campbell has received speakers Honoria from Biosense Webster. All other authors have reported no other relationships relevant to the contents of this paper to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}